If you have been reading about incretin and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-01-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Lyophilised material appears as a white to off-white cake or powder that is hygroscopic, and containers are usually equilibrated to room temperature before opening to limit condensation. Dissolution is performed in water, phosphate-buffered saline, or a mildly alkaline buffer, since solubility rises above neutral pH. Gentle inversion or low-speed mixing is preferred, because vigorous vortexing can promote surface denaturation and aggregation. Complete dissolution may require several minutes, and brief sonication is sometimes applied. Passing the solution through a 0.22 micrometre membrane removes particulates but does not by itself sterilise the liquid.
Storage at minus 20 degrees Celsius or lower in a desiccated container preserves the peptide for extended periods, while working solutions are commonly held at two to eight degrees Celsius for short intervals. Light exposure and repeated freeze-thaw cycles accelerate degradation, so dividing material into single-use aliquots is generally recommended. Adsorption to glass and plastic surfaces can lower the measured concentration of dilute solutions, particularly below one milligram per millilitre. The degradation routes most often reported for GLP-1 analogues are deamidation, methionine oxidation, and backbone hydrolysis. Relative rates under specific conditions are frequently described only for individual formulations.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 or 280 nanometres is widely used to assess purity and to resolve related impurities. Liquid chromatography coupled to mass spectrometry confirms identity through the protonated molecular ion and fragment ions formed in tandem experiments. Capillary electrophoresis and peptide mapping after enzymatic digestion supply complementary information on charge variants and modification sites. Circular dichroism and nuclear magnetic resonance can report on secondary structure in solution. Absolute quantification usually depends on an external standard, and reported purity depends on the detection wavelength and integration parameters chosen.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Acylated GLP-1 receptor agonist | 31-residue synthetic peptide |
| Molecular formula | C187H291N45O59 | established for the free peptide |
| Appearance | White to off-white powder | as supplied before formulation |
| Solubility | Freely soluble in water | aqueous buffers near neutral pH |
| Typical storage | 2 to 8 degrees Celsius, protected from light | powder and solution forms differ in shelf life |
Semaglutide dissolves readily in water and in aqueous buffers near neutral pH. Solubility decreases near the isoelectric point, where net charge is minimal. Common laboratory solvents include phosphate-buffered saline and dilute ammonium bicarbonate. Strongly acidic or basic conditions may accelerate hydrolysis. Working concentrations are usually prepared by diluting a concentrated stock. Vial surfaces can adsorb small amounts of peptide at low concentrations, so carrier proteins or low-binding tubes are sometimes used.
Reverse-phase high-performance liquid chromatography is the standard method for purity assessment, separating the peptide from truncated or oxidized variants. Mass spectrometry confirms molecular mass and detects modifications, while ultraviolet absorbance near 280 nanometers supports concentration measurement through tryptophan and tyrosine residues. Circular dichroism can indicate secondary structure, though the peptide is largely helical in solution, and ion-exchange chromatography resolves charge variants. Purity values above 95 percent are typical for research-grade material. Stability studies track degradation over time under defined conditions.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
== External links == GeneReviews/NCBI/NIH/UW entry on Pseudoachondroplasia GeneReviews/NCBI/NIH/UW entry on Multiple Epiphyseal Dysplasia, Dominant cartilage+matrix+protein at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
Bragg on X-ray crystallography, "Concerning the Nature of Things", which helped her decide her future. She was further encouraged by the chemist A.F. Joseph, a family friend who also worked in Sudan. Her state school education did not include Latin, then required for entrance to Oxbridge. Her Leman School headmaster, George Watson, gave her personal tuition in the subject, enabling her to pass the University of Oxford entrance examination. When Hodgkin was asked in later life to name her childhood heroes, she named three women: first and foremost, her mother, Molly; the medical missionary Mary Slessor; and Margery Fry, the Principal of Somerville College.
=== Post-war === The division suffered 995 killed and 7,082 wounded, for a total of 8,077 casualties. Following the war's end, the division moved to training areas near Prauthoy, where it remained to February 1919. It returned to the United States in April and May, and was demobilized and deactivated at Camp Mills, New York, on 27 May.
Sources: en.wikipedia.org
There he again showed the image of parabolic patches of light on the photographic plate (see image), which suggested two species of neon nuclei with different mass-to-charge ratios. He wrote "There can, therefore, I think, be little doubt that what has been called neon is not a simple gas but a mixture of two gases, one of which has an atomic weight about 20 and the other about 22. The parabola due to the heavier gas is always much fainter than that due to the lighter, so that probably the heavier gas forms only a small percentage of the mixture." F. W. Aston subsequently discovered multiple stable isotopes for numerous elements using a mass spectrograph, related to Thomson's method. In 1919 Aston studied neon with sufficient resolution to show that the two isotopic masses are very close to the integers 20 and 22, and that neither is equal to the known molar mass (20.2) of neon gas. This is an example of Aston's whole number rule for isotopic masses, now known to be exceptionless, which states that large deviations of elemental molar masses from integers are due to the fact that the element is a mixture of isotopes. Aston similarly showed in 1920 that the molar mass of chlorine (35.45) is a weighted average of the almost integral masses for the two isotopes 35Cl and 37Cl.
=== HIV/AIDS === Baricitinib has been investigated for its potential to reduce the HIV reservoir and chronic inflammation in people infected with HIV. Preclinical studies in humanized mice and non-human primates have demonstrated that the drug can penetrate the blood-brain barrier and reach therapeutic concentrations in the central nervous system (CNS). In these models, baricitinib was associated with a reduction in cellular activation markers, lower frequencies of infected macrophages in the brain, and improvements in HIV-associated behavioral deficits. Research suggests that by blocking the JAK-STAT signaling pathway, the drug may limit the survival of infected cells and prevent the reseeding of viral reservoirs in sanctuary sites like the CNS, which are often poorly reached by standard antiretroviral therapy (ART). As of 2025, baricitinib is currently being evaluated in multiple Phase II clinical trials to assess its safety and efficacy as an adjunctive therapy to ART. One primary area of focus is its ability to decrease or clear the CNS reservoir, with ongoing trials monitoring changes in cerebrospinal fluid (CSF) viral DNA and neurocognitive function. Additional studies are examining its impact on systemic inflammation, cell survival pathways, and the delay of viral rebound during monitored treatment interruptions.
=== Activity against AIDS-associated gut damage === As a result of initial HIV infection, the gut has been found to be a prime center of immune activity. The immune systems' Paneth cells of the gut attack HIV by producing interleukin 1 beta (IL-1β), which results in extensive collateral damage—sloughing of tight intestinal lining, witnessed as severe diarrhea. This destruction of the gut lining allows fungal pathogens to invade, e.g., Cryptococcus species, resulting in an AIDS-defining illness such as cryptococcosis, representing 60% to 70% of all AIDS-defining cases, but not necessarily only the gut. In rhesus macaques, L. plantarum is able to reduce (destroy) IL-1β, resolving inflammation, and accelerating gut repair within hours.
==== Liquid crystal microcapsules ==== Fabrication of liquid crystals has been a point of intrigue for over 5 decades for their anisotropic properties. Microfluidic devices can be used for the synthesis of confined cholesteric liquid crystals through layering of multiple shell-like layers consisting of varying oil-in-water and water-in-oil emulsions. The construction of encapsulated liquid crystals through microfluidic flow of liquid crystal droplets in an immiscible oil allows for monodispersed emulsion layer thickness and composition previously unseen before the advent of microfluidic techniques. The advent of liquid crystal technology has led to advancements in optical displays used both in research and consumer branded products, but more recent discoveries have opened the door to the combination of photon combination and upconversion as well as optical sensors for biological analytes.
Sources: en.wikipedia.org
==== Withdrawn ==== Jon Bonck, mortgage broker (running in the 38th district) Valentina Gomez, financial strategist and candidate for Missouri secretary of state in 2024 (ran in the 31st district) Nick Tran, businessman (ran in the 8th district)
This process is in contrast to the histopathologic changes seen in usual interstitial pneumonia where extensive fibrosis and inflammation occur leading to fibroblastic foci to form in the alveolar spaces resulting in obliteration of the alveolar space, scarring and significant damage to lung architecture (the alveoli). Tissue inhibitors of metalloproteinases (which inhibit breakdown of the extracellular matrix connective tissue) are more active in usual interstitial pneumonia as compared to organizing pneumonia, this is thought to lead to a greater deposition of connective tissue in the alveolar space in interstitial pneumonia as compared to organizing pneumonia and may explain the progressive, irreversible fibrosis seen in usual interstitial pneumonia. Gelatinolytic activity (resulting in the breakdown of extracellular matrix connective tissue) is greater in organizing pneumonia as compared to usual interstitial pneumonia, and this is thought to contribute to the reversible fibroproliferation characteristic of organizing pneumonia.
=== Beyond Raw === GNC is a company that offers creatine supplements in both pill and powder forms through its GNC AMP® and Beyond Raw® Chemistry Labs product lines. Their products have been scientifically supported and clinically tested, such as the GNC AMP® Creatine HCl 189™. In collaboration with The Hershey Company, products like Beyond Raw® LIT™ JOLLY RANCHER Grape pre-workout powder and on the-go have been produced which come in flavours like watermelon, green apple, and blue raspberry. Each pre-workout supplement contains clinically dosed ingredients, such as L-Citrulline, CarnoSyn betaalanine, micronized creatine, caffeine, and Nitrosigine. Other supplements like Burn MF Metabolic Activator Powder, Capsules, Sticks, and Drink belong to the Beyond Raw brand. Additionally, the text mentions that a new flavor, JOLLY RANCHER Grape, has been launched after the release of another supplement called Beyond Raw Concept X in May 2022. However, in a settlement with the Department of Justice, GNC, the largest retailer of supplements in the country, has agreed to pay $2.25 million. This settlement comes as part of a larger effort by the federal government to crack down on supplements that contain undisclosed drug ingredients, harmful compounds, or inaccurate ingredient labeling. As part of the settlement, GNC has committed to improving its product screening process and removing any supplements containing illegal or unsafe ingredients. In addition, the company will maintain a list of products that have been deemed safe for sale.
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and neutral endopeptidases. Semaglutide carries a non-natural amino acid at position eight that blocks that cleavage, and a fatty diacid side chain that binds albumin. The result is a much longer duration of action than the native hormone.
The fatty diacid chain associates strongly with serum albumin, which keeps the peptide in circulation and shields it from rapid renal clearance. Bound peptide is released gradually, producing a sustained receptor signal. This mechanism also reduces the peak-to-trough variation seen with shorter-acting analogues.
The balance between peripheral receptor activation and signalling in the central nervous system is not fully resolved. The extent to which slowed gastric emptying accounts for reduced energy intake, compared with direct effects on appetite circuits, is debated. Long-term effects on lean mass and on tissues outside the gut and brain are still under study.
Filtering removes particulate matter that can block columns or scatter light. A 0.22 micrometre membrane is typical, and the filter material should be checked for peptide adsorption.